About Neuronal migration protein doublecortin
Neuronal migration protein doublecortin (DCX) is a protein
from Homo sapiens identified by UniProt accession
O43602, 365 residues long.
MolForge cross-references it against 0 known binders and
346 disease associations.
Target properties
| Protein name | Neuronal migration protein doublecortin |
| UniProt accession | O43602 |
| Gene | DCX |
| Organism | Homo sapiens |
| Length | 365 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (346)
Diseases linked to this target (Open Targets).
- lissencephaly type 1 due to doublecortin gene mutation · score 0.86
- subcortical band heterotopia · score 0.63
- Non-syndromic cerebral malformation due to abnormal neuronal migration · score 0.56
- Abnormal cortical gyration · score 0.52
- genetic disorder · score 0.51
- Neurodevelopmental disorder · score 0.37
- lissencephaly spectrum disorders · score 0.37
- Lissencephaly · score 0.36
- Abnormality of the nervous system · score 0.34
- fucosidosis · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43602-F1 | alphafold | PREDICTED | 66.49 | — |
Amino-acid sequence (365 residues)
MELDFGHFDE RDKTSRNMRG SRMNGLPSPT HSAHCSFYRT RTLQALSNEK KAKKVRFYRN GDRYFKGIVY AVSSDRFRSF DALLADLTRS LSDNINLPQG VRYIYTIDGS RKIGSMDELE EGESYVCSSD NFFKKVEYTK NVNPNWSVNV KTSANMKAPQ SLASSNSAQA RENKDFVRPK LVTIIRSGVK PRKAVRVLLN KKTAHSFEQV LTDITEAIKL ETGVVKKLYT LDGKQVTCLH DFFGDDDVFI ACGPEKFRYA QDDFSLDENE CRVMKGNPSA TAGPKASPTP QKTSAKSPGP MRRSKSPADS GNDQDANGTS SSQLSTPKSK QSPISTPTSP GSLRKHKDLY LPLSLDDSDS LGDSM
Explore Neuronal migration protein doublecortin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets